HUT77002A - Tachikininantagonista vegyületek - Google Patents

Tachikininantagonista vegyületek Download PDF

Info

Publication number
HUT77002A
HUT77002A HU9701897A HU9701897A HUT77002A HU T77002 A HUT77002 A HU T77002A HU 9701897 A HU9701897 A HU 9701897A HU 9701897 A HU9701897 A HU 9701897A HU T77002 A HUT77002 A HU T77002A
Authority
HU
Hungary
Prior art keywords
phenyl
hydrogen
formula
compounds
oxygen
Prior art date
Application number
HU9701897A
Other languages
English (en)
Hungarian (hu)
Inventor
Soo Young Ko
Christopher Walpole
Original Assignee
Novartis Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9425085.9A external-priority patent/GB9425085D0/en
Priority claimed from GBGB9426016.3A external-priority patent/GB9426016D0/en
Application filed by Novartis Ag. filed Critical Novartis Ag.
Publication of HUT77002A publication Critical patent/HUT77002A/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HU9701897A 1994-12-13 1995-12-12 Tachikininantagonista vegyületek HUT77002A (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9425085.9A GB9425085D0 (en) 1994-12-13 1994-12-13 Organic compounds
GBGB9426016.3A GB9426016D0 (en) 1994-12-22 1994-12-22 Organic compounds

Publications (1)

Publication Number Publication Date
HUT77002A true HUT77002A (hu) 1998-03-02

Family

ID=26306161

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9701897A HUT77002A (hu) 1994-12-13 1995-12-12 Tachikininantagonista vegyületek

Country Status (17)

Country Link
EP (1) EP0797583A1 (fr)
JP (1) JPH10511935A (fr)
AR (1) AR001332A1 (fr)
AU (1) AU4343796A (fr)
BR (1) BR9509997A (fr)
CA (1) CA2204130A1 (fr)
CO (1) CO4700289A1 (fr)
CZ (1) CZ179097A3 (fr)
FI (1) FI971685A (fr)
HU (1) HUT77002A (fr)
IL (1) IL116323A0 (fr)
NO (1) NO972526D0 (fr)
PE (1) PE38997A1 (fr)
PL (1) PL320217A1 (fr)
SK (1) SK74697A3 (fr)
TR (1) TR199501568A2 (fr)
WO (1) WO1996018643A1 (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6117855A (en) 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
CA2266773A1 (fr) * 1996-10-07 1998-04-16 Merck Sharp & Dohme Limited Utilisation de l'antagoniste du recepteur nk-1 utilise comme antidepresseur et/ou agent anxiolytique
CN1157224C (zh) 1999-02-18 2004-07-14 科研制药株式会社 用作生长激素促分泌剂的新酰胺衍生物
NZ552397A (en) 2004-07-15 2011-04-29 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
WO2006123182A2 (fr) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Sulfones de cyclohexyle pour le traitement du cancer
KR20080044840A (ko) 2005-07-15 2008-05-21 에이엠알 테크놀로지, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기위한 용도
EP1940842B1 (fr) 2005-09-29 2012-05-30 Merck Sharp & Dohme Corp. Dérivés acylés de spiropipéridine en tant que modulateurs du récepteur de la mélanocortine-4
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
JP5489333B2 (ja) 2006-09-22 2014-05-14 メルク・シャープ・アンド・ドーム・コーポレーション 脂肪酸合成阻害剤を用いた治療の方法
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
PL2336120T3 (pl) 2007-01-10 2014-12-31 Msd Italia Srl Kombinacje zawierające indazole podstawione grupą amidową jako inhibitory polimerazy poli(ADP-rybozy) (PARP)
US8093268B2 (en) 2007-01-24 2012-01-10 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-)
EP2145884B1 (fr) 2007-04-02 2014-08-06 Msd K.K. Dérivé d'indoledione
AU2008269154B2 (en) 2007-06-27 2014-06-12 Merck Sharp & Dohme Llc 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
JP2011515343A (ja) 2008-03-03 2011-05-19 タイガー ファーマテック チロシンキナーゼ阻害薬
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
WO2010132442A1 (fr) 2009-05-12 2010-11-18 Albany Molecular Reserch, Inc. 7-([1,2, 4,]triazolo[1,5,-a]pyridine-6-yl)-4-(3,4-dichlorophényl)-1,2,3,4- tétrahydroisoquinoline et son utilisation
EP2429295B1 (fr) 2009-05-12 2013-12-25 Albany Molecular Research, Inc. Aryle, hétéroaryle et tétrahydroisoquinolines à hétérocycle substitué et leur utilisation
EP2429293B1 (fr) 2009-05-12 2014-10-29 Bristol-Myers Squibb Company FORMES CRISTALLINES DE (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN -6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE ET LEURS UTILISATIONS
WO2011046771A1 (fr) 2009-10-14 2011-04-21 Schering Corporation Pipéridines substituées qui accroissent l'activité de p53, et utilisations de ces composés
WO2011163330A1 (fr) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Nouveaux composés hétérocycliques utilisés comme inhibiteurs de erk
CA2805265A1 (fr) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. Inhibition a mediation par interference arn de catenine (proteine associee a cadherine), expression du gene beta 1 (ctnnb1) a l'aide de petit acide nucleique interferent (sian)
CA2807307C (fr) 2010-08-17 2021-02-09 Merck Sharp & Dohme Corp. Inhibition mediee par des arn interferents de l'expression genique du virus de l'hepatite b (vhb) a l'aide de petits acides nucleiques interferents (pani)
EP2608669B1 (fr) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. Nouveaux dérivés de pyrazolo[1,5-a]pyrimidine utilisés comme inhibiteurs de mtor
WO2012030685A2 (fr) 2010-09-01 2012-03-08 Schering Corporation Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk
EP2615916B1 (fr) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Dérivés condensés de pyrazole utilisés comme nouveaux inhibiteurs erk
ES2663009T3 (es) 2010-10-29 2018-04-10 Sirna Therapeutics, Inc. Inhibición de la expresión génica mediada por interferencia por ARN utilizando ácidos nucleicos de interferencia cortos (ANic)
EP2654748B1 (fr) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Dérivés d'indazole utiles en tant qu'inhibiteurs de erk
JP2014514321A (ja) 2011-04-21 2014-06-19 メルク・シャープ・アンド・ドーム・コーポレーション インスリン様増殖因子１受容体阻害剤
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
EP3358013B1 (fr) 2012-05-02 2020-06-24 Sirna Therapeutics, Inc. Compositions d'acide nucléique interférent court (sina)
JP6280554B2 (ja) 2012-09-28 2018-02-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｅｒｋ阻害剤である新規化合物
BR112015012295A8 (pt) 2012-11-28 2023-03-14 Merck Sharp & Dohme Uso de um inibidor de wee1, e, kit para identificar um paciente com câncer
MX2015008196A (es) 2012-12-20 2015-09-16 Merck Sharp & Dohme Imidazopiridinas sustituidas como inhibidores de doble minuto 2 humana.
WO2014120748A1 (fr) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. Purines 2,6,7,8-substituées utilisées en tant qu'inhibiteurs de hdm2
EP3041938A1 (fr) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Polynucléotides circulaires
WO2018071283A1 (fr) 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Inhibiteurs de kdm5
WO2019094311A1 (fr) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
EP3706747A4 (fr) 2017-11-08 2021-08-04 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
EP3833668A4 (fr) 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
EP3833667B1 (fr) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Inhibiteurs de prmt5

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5164372A (en) * 1989-04-28 1992-11-17 Fujisawa Pharmaceutical Company, Ltd. Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same
JPH05186498A (ja) * 1991-12-27 1993-07-27 Japan Tobacco Inc プロリン誘導体

Also Published As

Publication number Publication date
CA2204130A1 (fr) 1996-06-20
JPH10511935A (ja) 1998-11-17
AR001332A1 (es) 1997-10-22
FI971685A0 (fi) 1997-04-18
PE38997A1 (es) 1997-10-02
EP0797583A1 (fr) 1997-10-01
IL116323A0 (en) 1996-03-31
NO972526L (no) 1997-06-03
NO972526D0 (no) 1997-06-03
FI971685A (fi) 1997-08-13
CZ179097A3 (en) 1997-10-15
AU4343796A (en) 1996-07-03
CO4700289A1 (es) 1998-12-29
SK74697A3 (en) 1997-11-05
WO1996018643A1 (fr) 1996-06-20
BR9509997A (pt) 1997-12-30
PL320217A1 (en) 1997-09-15
MX9703957A (es) 1997-09-30
TR199501568A2 (tr) 1996-07-21

Similar Documents

Publication Publication Date Title
HUT77002A (hu) Tachikininantagonista vegyületek
ES2338539T3 (es) Pirazolamidas para uso en el tratamiento del dolor.
JPH06507405A (ja) ピロリジノン類
JPH10511695A (ja) Ｎ−（アロイル）グリシンヒドロキサム酸誘導体および関連化合物
SK3612000A3 (en) Sustained release tablet formulation to treat parkinson disease
JP2008517020A (ja) Ｍｉｆ阻害剤
JP2001261663A (ja) Ｉｍｐｄｈ阻害剤としてのオキサミド類
JP3817256B2 (ja) タキキニンアンタゴニスト
CN104582709A (zh) 作为a2a激动剂的n-烷基2-(双取代的)炔基腺苷-5’-糖醛酰胺
CA2589744A1 (fr) Derives de pyrrolinidium utilises comme recepteurs m3 muscariniques
JP2000327575A (ja) ジケトピペラジン誘導体含有炎症疾患治療剤および新規なジケトピペラジン誘導体
JPH10508847A (ja) 酸化窒素合成酵素インヒビターとして有用なアミノテトラゾール誘導体
US7001915B2 (en) Ultrashort-acting opioids for transdermal applications
CN103237795B (zh) 经取代的噁二唑化合物及其作为s1p1激动剂的用途
KR20010034317A (ko) Ｖｌａ-4 길항제
TW201006799A (en) Novel compounds active as muscarinic receptor antagonists
WO2000041685A1 (fr) Antagonistes des recepteurs ccr-3
US4868175A (en) 4-Benzyl-1-(2H)-phthalazineone derivatives having an amino acid radical
JP2824661B2 (ja) アザ環式カルボン酸誘導体及びその調剤並びに使用
WO2019042187A1 (fr) Composé aminopyrimidine, composition le comprenant et utilisation associée
TW200934769A (en) Trisubstituted 1,2,4-triazoles
JPS6230762A (ja) 新規５−オキソ−１−イミダゾリジンアセトアミド誘導体
HU205920B (en) Process for producing 2-phenoxy-methyl/-3-/alkanoyl-, carboxy-, carbalkoxy- or carboxamido- -acetyl/-1,3-thiazolidine derivatives and pharmaceutical compositions containing them
US20150307548A1 (en) Fpr1 antagonist derivatives and use thereof
WO2001062293A1 (fr) Medicaments preventifs ou therapeutiques contenant des inhibiteurs de chymase en tant que principe actif, pour traiter diverses maladies associees a l'eosinophilie

Legal Events

Date Code Title Description
DFD9 Temporary protection cancelled due to non-payment of fee